Literature DB >> 15488616

Large-scale production, purification and crystallization of wild-type adeno-associated virus-2.

Qing Xie1, Joan Hare, Joy Turnigan, Michael S Chapman.   

Abstract

Adeno-associated virus-2 (AAV-2) has long been recognized as a potential vector for human gene therapy. Although much progress has been made in the molecular virology of AAV-2, structural studies of AAV-2 have been hampered by the low efficiency of virus production in culture, the low purity of preparations, and the low solubility of pure virus particles in solution. Methods of larger scale AAV-2 production have been developed through adaptation to suspension culture and re-optimization of the times of infection and transfection with respect to particle production. The methods allow the purification of 10mg ( approximately 10(15) particles) of AAV-2 per preparation at approximately 99% purity as judged by SDS-PAGE. This was sufficient for the screening of conditions for the formation of diffraction-grade crystals, ultimately leading to an atomic structure for AAV-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488616     DOI: 10.1016/j.jviromet.2004.07.007

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  23 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

2.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

3.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

4.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1.

Authors:  Edward B Miller; Brittney Gurda-Whitaker; Lakshmanan Govindasamy; Robert McKenna; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

5.  Proteolytic mapping of the adeno-associated virus capsid.

Authors:  Kim Van Vliet; Veronique Blouin; Mavis Agbandje-McKenna; Richard O Snyder
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

6.  Twinned crystals of adeno-associated virus serotype 3b prove suitable for structural studies.

Authors:  Thomas F Lerch; Qing Xie; Heather M Ongley; Joan Hare; Michael S Chapman
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

7.  Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6.

Authors:  Qing Xie; Heather M Ongley; Joan Hare; Michael S Chapman
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-10-31

8.  Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry.

Authors:  Sarah Murray; Carol L Nilsson; Joan T Hare; Mark R Emmett; Andrei Korostelev; Heather Ongley; Alan G Marshall; Michael S Chapman
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion.

Authors:  Thomas F Lerch; Qing Xie; Michael S Chapman
Journal:  Virology       Date:  2010-05-04       Impact factor: 3.616

10.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.